FDG and FAPI PET–based response evaluation to reduced‐dose nivolumab in pleural mesothelioma: A case report
Abstract
Abstract Reliable tools for objective response assessment are essential in pleural mesothelioma treated with immunotherapy. We report on a 75‐year‐old man with sarcomatoid pleural mesothelioma who received a reduced nivolumab dose after developing a hypersensitivity reaction during the first infusion. CT, [ 18 F]FDG PET/CT and [ 68 Ga]Ga‐Fibroblast activation protein inhibitor‐46 (FAPI) PET/CT were performed before and after treatment. Despite the reduced dose, the patient experienced clear clinical benefit, and follow‐up imaging demonstrated substantial morphological and metabolic improvement across all imaging modalities. This case offers an unique opportunity to directly compare response assessment across three complimentary imaging modalities.
Fields of Study & Subjects
Peptidase Inhibition and Analysis
Occupational and environmental lung diseases
Bladder and Urothelial Cancer Treatments
Publication details
- Journal / source
- Clinical Physiology and Functional Imaging
- Publisher
- Wiley
- Volume
- 46
- Issue
- 2
- Pages
- e70053–e70053
- Publication date
- 19 February 2026
- Language
- EN